Decheng Capital operates as an investment firm, extending capital and strategic assistance to early-stage life science companies boasting innovative technologies, as well as growth-stage healthcare firms with established market traction. Established in 2012, Decheng persistently leverages the burgeoning healthcare sector's rapid expansion and breakthroughs in life science research. With a capital base exceeding $2 billion and backing from renowned limited partners globally, Decheng stands primed to generate value for both its investors and entrepreneurial partners.
Dr. Min Cui leads as the Founder and Managing Director of Decheng Capital, directing efforts towards global biotechnology and medical technology ventures. His roles extend to board memberships in various companies such as Alpine Immune Sciences, Bioheng, EpimAb Biotherapeutics, Harton Therapeutics, ImmPACT Bio, Mammoth Biosciences, Mirvie, and Shape Therapeutics. Past involvements include directorial positions at institutions like Bay City Capital and the Southern Research Institute, where he contributed significantly to the development of anti-cancer drugs approved by the US FDA. Dr. Cui's academic background includes a PhD in Cancer Biology from Stanford University and BS/MS degrees in Molecular Biology from Peking University. Presently, he serves as a board of trustee at Western University of Health Sciences.
Decheng Capital manages assets totaling $1,977,628,753 according to their most recent Form ADV from March 2024. Their last reported 13F filing for Q4 2023 showcased $357,920,713 in managed securities, with a significant 84.63% concentration in their top 10 holdings. Alpine Immune Sciences Inc stands as their largest holding, with 7,083,288 shares held.
